October 28, 2020
Synspira Therapeutics Adds Drucy Borowitz, MD, to Board of Directors
Alexey Margolin, PhD, Appointed Chairperson
Mass., October 28, 2020 — Synspira Therapeutics, a clinical-stage biopharmaceutical company dedicated to improving the lives of people with cystic fibrosis (CF) and other rare diseases, today announced the appointment of Drucy Borowitz, MD, to its Board of Directors. Dr. Borowitz is a global leader in clinical research and patient care for cystic fibrosis (CF) with particular expertise in gastrointestinal disease and nutrition. The company also announced that current board member, Alexey Margolin, PhD, will take on an expanded role as chairperson of the Board of Directors.
“We are delighted to welcome Dr. Borowitz to our Board of Directors. She is a recognized leader and expert in CF, known for her achievements advancing therapies through clinical development and championing unique initiatives highlighting the important role of the patient in clinical development,” said Robert Gallotto, president and chief executive officer, Synspira Therapeutics. “Dr. Borowitz is an outstanding and important addition to our Board and I know she will provide important insights and extend our thinking as we grow and begin to execute on our long-term strategy.”
Dr. Drucy Borowitz is the former senior vice president of community partnerships at the Cystic Fibrosis Foundation where she led numerous initiatives to improve patient care and advance new Treatments.
Dr. Borowitz was the CF center director at the Women and Children’s Hospital of Buffalo for almost 20 years. In 2013, she received the Richard C. Talamo Distinguished Clinical Achievement Award presented by the Cystic Fibrosis Foundation to individuals dedicated to the research and care of patients with cystic fibrosis and whose contributions have had considerable influence on the course of the disease. Dr. Borowitz is an emeritus professor of clinical pediatrics at the Jacobs School of Medicine and Biomedical Sciences of the University at Buffalo. She received the Stockton Kimball Award, bestowed on faculty members who have achieved worldwide recognition as researchers and have been recognized for significant academic accomplishment and service to the university. Dr. Borowitz attended Cornell Medical School, interned at Children’s Hospital of Philadelphia, and did her residency at University of California-San Francisco. She was board certified in pediatric gastroenterology and nutrition.
“I am honored to join Synspira at such an exciting time for the company and to work with a team that has a track record of bringing important products to the CF community,” said Dr. Borowitz. “Synspira’s clinical programs are moving ahead quickly, and I am looking forward to helping the company continue to advance its mission of developing important treatments for people with CF and other rare disease.”
Synspira also announced today that Alexey Margolin, PhD, has been appointed chair of the Board of Directors. Dr. Margolin joined the company’s board in October 2019.
Dr. Alexey Margolin is chair of the Board of Allena Pharmaceuticals, a public clinical stage pharmaceutical company he co-founded, and previously served as CEO (2011-2019). Prior, he co-founded Alcresta Therapeutics, a medical device company focused on developing products for CF and other rare diseases; he served as CEO (2011-2014) and is currently on the board of directors. In 2008, Dr. Margolin co-founded Alnara Pharmaceuticals, and served as president and CEO until 2010, when the company was acquired by Eli Lilly. As chief scientific officer for Altus Pharmaceuticals, he helped build a portfolio of products for rare diseases. Dr. Margolin is the author of more than 60 publications and an inventor on numerous patents.
“The Synspira team brings significant experience and is committed to developing novel therapies that can change the way CF and other debilitating rare diseases are treated,” said Alexey Margolin, PhD, chairperson of the Board of Directors, Synspira Therapeutics. “I look forward to continuing to help build momentum and advance the company’s clinical program, including its lead compound, SNSP113, for the treatment of life-threatening pulmonary conditions and SNSP003, its oral enzyme therapy for the treatment of Malabsorption Syndromes.”
About Synspira Therapeutics
Synspira Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to significantly improving the lives of people with cystic fibrosis (CF) and other rare diseases. Inspired by patients, Synspira is focused on developing a rationally designed portfolio of products that can make a life-changing impact and improve the quality of life of our patients. Synspira is working to advance two novel products (SNSP113 and SNSP003) intended to provide better clinical outcomes and reduce treatment burden in pulmonary disease as well as malabsorption syndromes and exocrine pancreatic insufficiency. SNSP113, Synspira’s lead product, is in a Phase 2 clinical study in people with cystic fibrosis. Synspira is a privately held company headquartered in Framingham, MA.
# # #
(781) 799-3137 (mobile)